Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector.
Rift Valley fever virus (RVFV) causes recurrent large outbreaks among humans and livestock. Although the virus is currently confined to the African continent and the Arabian Peninsula, there is a growing concern for RVFV incursions into countries with immunologically naïve populations. The RVFV structural glycoproteins Gn and Gc are preferred targets in the development of subunit vaccines that can be used to control future outbreaks. We here report the production of Gn and Gc by a recombinant vaccine strain of the avian paramyxovirus Newcastle disease virus (NDV) and demonstrate that intramuscular vaccination with this experimental NDV-based vector vaccine provides complete protection in mice. We also demonstrate that a single intramuscular vaccination of lambs, the main target species of RVFV, is sufficient to elicit a neutralizing antibody response.
Kortekaas
J
J
Central Veterinary Institute of Wageningen University Research Centre, AB Lelystad, The Netherlands. jeroen.kortekaas@wur.nl
de Boer
S M
SM
Kant
J
J
Vloet
R P M
RP
Antonis
A F G
AF
Moormann
R J M
RJ
D000818:Animals; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D009522:Newcastle disease virus / Q000276:immunology*; D012295:Rift Valley Fever / Q000276:immunology* / Q000517:prevention & control; D012296:Rift Valley fever virus / Q000276:immunology* / Q000472:pathogenicity; D012756:Sheep; D014765:Viral Vaccines / Q000276:immunology*
D014765:Viral Vaccines